Aptose Biosciences Inc. (APTO)
NASDAQ: APTO · IEX Real-Time Price · USD
1.231
-0.039 (-3.07%)
At close: Apr 19, 2024, 3:58 PM
1.230
-0.001 (-0.08%)
After-hours: Apr 19, 2024, 5:52 PM EDT
Aptose Biosciences Stock Forecast
APTO's stock price has decreased by -83.59% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Aptose Biosciences stock have an average target of 19.8, with a low estimate of 5.00 and a high estimate of 38. The average target predicts an increase of 1,508.45% from the current stock price of 1.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APTO stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $5 | Buy | Maintains | $5 | +306.17% | Apr 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +1,768.40% | Mar 27, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $12 → $5 | Buy | Maintains | $12 → $5 | +306.17% | Feb 1, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $23 → $18 | Buy | Maintains | $23 → $18 | +1,362.23% | Nov 10, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $38 | Buy | Reiterates | $38 | +2,986.92% | Sep 7, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
517.12K
EPS This Year
-4.31
from -7.58
EPS Next Year
-2.74
from -4.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 1.6M | n/a | 173.1M | 312.4M |
| Avg | n/a | 517,120 | n/a | 166.5M | 300.5M |
| Low | n/a | n/a | n/a | 161.6M | 291.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 87.7% |
| Avg | - | - | - | - | 80.5% |
| Low | - | - | - | - | 75.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.75 | -1.06 | -0.77 | 0.47 | 2.74 |
| Avg | -4.31 | -2.74 | -0.74 | 0.46 | 2.63 |
| Low | -8.61 | -3.95 | -0.72 | 0.44 | 2.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 501.2% |
| Avg | - | - | - | - | 478.3% |
| Low | - | - | - | - | 461.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.